TX-FLUENCE
9.2.2021 14:02:12 CET | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial food and cannabis production, and Great Northern Hydroponics, an Ontario, Canada-based greenhouse growing more than 10 varieties of tomatoes, announced today that the companies’ collaborative LED implementation is projected to save an estimated 150,000 Canadian dollars in annual operating costs for the greenhouse. The project also qualified for an incentive through the Independent Electricity System Operator’s (IESO) Save on Energy Retrofit program that will significantly reduce the upfront costs of upgrading its lighting technology.
Great Northern Hydroponics’ 70-acre facility produces 20 million pounds of premium tomatoes annually. Its hydroponic greenhouses create optimum growing conditions through a sophisticated climate control system as well as a biologically controlled environment to prevent pest manifestations. Fluence’s LED technology was retrofitted across 10 acres of the facility’s tomato glasshouse. At the helm of Great Northern Hydroponics’ growing operation are Guido van het Hof, the company’s president and general manager, and Dean Bernardes, vice president of operations. Both hold decades of experience growing high-quality crops using the industry’s most advanced cultivation technology.
“We’ve been growing tomatoes for more than 20 years,” Van het Hof said. “As one of the first growers in our region to illuminate crops in a commercial environment, we’ve been immersed in researching and optimizing spectral strategies for plant growth and quality. Since the onset of LED technology, I’ve been particularly curious about how broad-spectrum LEDs could affect plant development. Based on our years of research and trialing, we’ve discovered that crops grow beautifully—with higher yields and fruit weights—under broad-spectrum light.”
Van het Hof’s multiyear commitment to researching the latest advancements and strategies for LED horticulture lighting rivals leading research universities and some of the world’s largest cultivators. In his pursuit to identify the optimal spectral strategy for vine crop production, Van het Hof spearheaded various trials with high-pressure sodium fixtures as well as LED technology. Throughout his decade-long exploration, Van het Hof has recorded significant advantages under broad-spectrum LED technology, reporting an increase in biomass and fruit production as well as significant energy savings—reductions which enabled the Great Northern Hydroponics team to leverage the Save on Energy Retrofit program offering growers incentives for energy-efficient lighting upgrades.
“Great Northern Hydroponics has always been a pioneer in leveraging horticulture technology and innovative cultivation methods,” said Steve Graves, vice president of business development for Fluence and long-time collaborator with Van het Hof. “Our work with Guido has informed some of our most important product advancements for vine crop growers throughout the world. Guido and his team at Great Northern Hydroponics have reinforced the validity and efficacy of LED lighting in greenhouse environments.”
Through Fluence’s utility rebate coordination program, the company assists growers with identifying, applying for and, in some cases, creating rebate programs in a facility’s respective region. With Great Northern Hydroponics’ lighting upgrade supported by the Save on Energy Retrofit program incentive, Van het Hof estimates the business will save approximately CA$150,000 in annual operational costs by replacing its high-pressure sodium lighting with Fluence’s LED technology.
“LED technology is proving to be superior across all categories,” Van het Hof added. “Our plants are flourishing under broad-spectrum lighting, our operational costs are decreasing and our staff is enjoying working with white light versus harsher, redder lights. It’s a win-win for everyone.”
For more information on Fluence and its rebate services, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005436/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
